ID: ALA206160

Max Phase: Preclinical

Molecular Formula: C29H35N3O6

Molecular Weight: 521.61

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)c2ccccc2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1

Standard InChI:  InChI=1S/C29H35N3O6/c1-5-6-17-22(23(33)25(34)30-19(2)20-13-9-7-10-14-20)31-28(37)38-24-27(36)32(18-29(24,3)4)26(35)21-15-11-8-12-16-21/h7-16,19,22,24H,5-6,17-18H2,1-4H3,(H,30,34)(H,31,37)/t19-,22+,24-/m1/s1

Standard InChI Key:  DESIODPKNCTHKC-WNOPAQSVSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 521.61

Molecular Weight (Monoisotopic): 521.2526

AlogP: 3.80

#Rotatable Bonds: 10

Polar Surface Area: 121.88

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.24

CX Basic pKa:

CX LogP: 4.93

CX LogD: 4.93

Aromatic Rings: 2

Heavy Atoms: 38

QED Weighted: 0.36

Np Likeness Score: -0.24

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature